Please login to the form below
Cipla
This page shows the latest Cipla news and features for those working in and with pharma, biotech and healthcare.
Pharma must do more on antibiotic resistance, Davos meeting hears
although Mylan, Cipla and Fresenius Kabi are doing the best when it comes to ‘stewardship’.
Latest news
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Clock ticking on biosimilar Enbrel in US
Meanwhile, in 2013, Indian drugmaker Cipla said it had launched its own Etacept version in its home market at a 30% discount to the brand.
-
London life science growth boosted by Takeda
Fourteen life science companies, including Pfizer, Takeda and India's Cipla, generated a total of £24.35m for London's economy in the 2014-15 financial year, creating a total of ... India is also a growing presence on the London life sciences scene with
-
India turns down patent on Gilead's Sovaldi
Cipla, Cadila Healthcare, Hetero, Strides Arcolab, Ranbaxy, Sequent Scientific and Mylan) at a 7% royalty rate.
-
Sovaldi deal for developing world ‘falls short’
In particular, there are concerns that the deal has been structured to thwart competition in middle-income countries as the companies involved - Cadila, Cipla, Hetero Labs, Mylan, Ranbaxy, Sequent Scientific and
More from news
Approximately 1 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2017
contingent payments for the ADHD company Neurovance; Shanghai Fosun paid $90m for a majority interest in Breas (see above); Ascendis Health paid R375m ($29m) for the Southern Africa operations of Cipla ... 60. Cipla Agrimed. Ascendis Health. Acquisition.
-
Pharma deals in September 2015
Collaboration - option to license. 555. Hetero Drugs. Cipla. Generic US based companies; InvaGen Pharmaceuticals and Exelar Pharmaceuticals.
-
Pharma deals during November 2012
The second generics acquisition is the offer of $215m by India's Cipla for a 51 per cent stake in South Africa's third largest drug company Cipla Medpro, again driven ... 230. Cipla Medpro / Cipla. Acquisition. Generics. 215. Ensemble Therapeutics /
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Cipla names Adil Zainulbhai to board
He has experience at consulting firm McKinsey &Company. India-based pharma company Cipla has appointed Adil Zainulbhai to its board as an independent director. ... Zainulbhai said: "Cipla has had a huge impact in providing affordable pharmaceuticals to
-
Cipla appoints Novartis’ Subhanu Saxena as CEO
Subhanu Saxena has left Novartis to join India-based generics company Cipla as its new CEO. ... Cipla's chair Dr Yusuf Hamied said: “We are delighted to have found such a good match for Cipla in Subhanu.
More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
Exploring MINT: Part 3 - Nigeria
At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
